Journal of Pharmacokinetics and Pharmacodynamics

, Volume 42, Issue 5, pp 429–446 | Cite as

Perspectives on the history and scientific contributions of Gerhard Levy

  • Ho-Leung Fung
  • William J. Jusko
Original Paper


Gerhard Levy (Fig.  1) was born February 12, 1928 in Wollin, Germany, and obtained his early education in China. An oral history of his childhood experiences in Nazi Germany and China is available online ( Gary attended the University of California at San Francisco earning the BS in Pharmacy in 1955 and PharmD in 1958. Nearly his entire career was spent at the University of Buffalo (UB) having joined as Assistant Professor of Pharmacy in 1958 and retiring as University Distinguished Professor of Pharmaceutics in 2000. His own personal perspectives on his career and the development of pharmacodynamics as a pharmaceutical science were published in the Annals of Pharmacotherapy in 2006 [ 1].


Pharmacokinetics Pharmacodynamics Pharmacy 


  1. 1.
    Levy G (2006) The development of pharmacodynamics as a pharmaceutical science: a personal perspective. Ann Pharmacother 40(3):520–523CrossRefPubMedGoogle Scholar
  2. 2.
    Levy G (1957) A method for the measurement of lubricating property of medicinals. J Am Pharm Assoc Sci Ed 46:558–561CrossRefGoogle Scholar
  3. 3.
    Levy G (1961) Comparison of dissolution and absorption rates of different commercial aspirin tablets. J Pharm Sci 50:388–392CrossRefPubMedGoogle Scholar
  4. 4.
    Levy G, Hayes BA (1960) Physicochemical basis of the buffered acetylsalicylic acid controversy. N Engl J Med 262:1053–1058CrossRefPubMedGoogle Scholar
  5. 5.
    Levy G, Nelson E (1961) Pharmaceutical formulation and therapeutic efficacy. JAMA 177:689–691CrossRefPubMedGoogle Scholar
  6. 6.
    Levy G (2011) Levy G, Hayes B, “Physiochemical basis of the buffered acetylsalicylic acid controversy. New Engl. J. Med. 262:1053–1058 (1960)”–the backstory. AAPS J 13(3):320–322PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Levy G (1961) Gastrointestinal bleeding from salicylates: role of route of administration, and relation to free hydrochloric acid. Gastroenterology 41:192–194PubMedGoogle Scholar
  8. 8.
    Levy G, Hollister LE (1964) Variation in rate of salicylate elimination by humans. Br Med J 2(5404):286–288PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Levy G, Tsuchiya T, Amsel LP (1972) Limited capacity for salicyl phenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man. Clin Pharmacol Ther 13(2):258–268PubMedGoogle Scholar
  10. 10.
    Levy G, Jusko WJ (1967) Case history of a pharmaceutical formulation failure. Clin Pharmacol Ther 8(6):887–889PubMedGoogle Scholar
  11. 11.
    Levy G, Tsuchiya T (1972) Salicylate accumulation kinetics in man. N Engl J Med 287(9):430–432CrossRefPubMedGoogle Scholar
  12. 12.
    Perrier D, Ashley JJ, Levy G (1973) Effect of product inhibition on kinetics of drug elimination. J Pharmacokin Biopharm 1:231–242CrossRefGoogle Scholar
  13. 13.
    Levy G, Galinsky RE, Lin JH (1982) Pharmacokinetic consequences and toxicologic implications of endogenous cosubstrate depletion. Drug Metab Rev 13(6):1009–1020CrossRefPubMedGoogle Scholar
  14. 14.
    Levy G (1998) Using other people’s data in publications. Am J Pharm Educ 62:371–373Google Scholar
  15. 15.
    Levy G (1964) Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J Pharm Sci 53:342–343CrossRefPubMedGoogle Scholar
  16. 16.
    Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7(3):362–372PubMedGoogle Scholar
  17. 17.
    Levy G (1970) Pharmacokinetics of succinylcholine in newborns. Anesthesiology 32(6):551–552CrossRefPubMedGoogle Scholar
  18. 18.
    Levy G, Gibaldi M, Jusko WJ (1969) Multicompartment pharmacokinetic models and pharmacologic effects. J Pharm Sci 58(4):422–424CrossRefPubMedGoogle Scholar
  19. 19.
    Nagashima R, Levy G, Nelson E (1968) Comparative pharmacokinetics of coumarin anticoagulants. I. Unusual interaction of bishydroxycoumarin with plasma proteins—development of a new assay. J Pharm Sci 57(1):58–67CrossRefPubMedGoogle Scholar
  20. 20.
    Nagashima R, O’Reilly RA, Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10(1):22–35PubMedGoogle Scholar
  21. 21.
    Levy G, Mager DE, Cheung WK, Jusko WJ (2003) Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 92(5):985–994CrossRefPubMedGoogle Scholar
  22. 22.
    Danhof M (2015) Kinetics of drug action in disease states—towards physiology-based pharmacodynamic (PBPD) models. J Pharmacokinet Pharmacodyn. doi: 10.1007/s10928-015-9437-x PubMedCentralGoogle Scholar
  23. 23.
    Danhof M, Levy G (1984) Kinetics of drug action in disease states. I. Effect of infusion rate on phenobarbital concentrations in serum, brain and cerebrospinal fluid of normal rats at onset of loss of righting reflex. J Pharmacol Exp Ther 229(1):44–50PubMedGoogle Scholar
  24. 24.
    Wilson TC, Levy G (1994) Kinetics of drug action in disease states. XLV. Effect of elevated plasma creatinine concentrations on the hypnotic action of phenobarbital in normal rats. J Pharm Sci 83(6):913–914CrossRefPubMedGoogle Scholar
  25. 25.
    Hayton WL, Guttman DE, Levy G (1972) Effect of complex formation on drug absorption. XI. Complexation of prednisone and prednisolone with dialkylpropionamides and its effect on prednisone transfer through an artificial lipoid barrier. J Pharm Sci 61(3):356–361CrossRefPubMedGoogle Scholar
  26. 26.
    Houston JB, Levy G (1976) Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. J Pharm Sci 65(8):1218–1221CrossRefPubMedGoogle Scholar
  27. 27.
    Levy G, Khanna NN, Soda DM, Tsuzuki O, Stern L (1975) Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and d-glucaric acid excretion. Pediatrics 55(6):818–825PubMedGoogle Scholar
  28. 28.
    Chou RC, Levy G (1984) Effect of folic acid on the pharmacokinetics of acutely administered phenytoin in pregnant and nonpregnant rats. J Pharm Sci 73(8):1180–1182CrossRefPubMedGoogle Scholar
  29. 29.
    Levy G (1986) Effect of protein binding on the pharmacologic activity of drugs as exemplified by warfarin. In: MM Reidenberg, S Erill (eds) Esteve foundation symposium, drug-protein binding. Praeger Publishers, New York, pp 317–331Google Scholar
  30. 30.
    Levy G (1980) Effect of plasma protein binding on renal clearance of drugs. J Pharm Sci 69(4):482–483CrossRefPubMedGoogle Scholar
  31. 31.
    Dave RA, Morris ME (2015) Semi-mechanistic kidney model incorporating physiological fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and l-lactate in rats. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9441-1
  32. 32.
    Levy G, Jusko WJ (1966) Factors affecting the absorption of riboflavin in man. J Pharm Sci 55(3):285–289CrossRefPubMedGoogle Scholar
  33. 33.
    Jusko WJ, Levy G (1970) Pharmacokinetic evidence for saturable renal tubular reabsorption of riboflavin. J Pharm Sci 59(6):765–772CrossRefPubMedGoogle Scholar
  34. 34.
    Yee SW, Lin L, Merski M, Keiser MJ, Gupta A, Zhang Y, Chien H-C, Shoichetet BK, Giacomini KM (2015) Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9436-y
  35. 35.
    Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56(3):248–252CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang L, Mager DE (2015) Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice. J Pharmacokinet Pharmcodyn 42. doi: 10.1007/s10928-015-9445-x
  37. 37.
    Glassmann PM, Chen Y, Balthasar, JP (2015) Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9444-y
  38. 38.
    Shah DK (2015) Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9447-8
  39. 39.
    Levy G, Zamacona MK, Jusko WJ (2000) Developing compliance instructions for drug labeling. Clin Pharmacol Ther 68(6):586–591CrossRefPubMedGoogle Scholar
  40. 40.
    Fellows K, Stoneking CJ, Ramanathan M (2015) Bayesian modeling of drug dosing adherence in populations. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9439-8
  41. 41.
    Zhu X, Straubinger RM, Jusko WJ (2015) Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9429-x
  42. 42.
    Krzyzanski W (2015) Pharmcodynamic models of age-structured cell populations. J Pharmacokinet Pharmacodyn 42. doi: 10.1007/s10928-015-9446-9
  43. 43.
    Reuning RH, Levy G (1967) Effect of complex formation on drug absorption. IV. Role of intragastric diffusion in the absorption of free and caffeine-complexed salicylic acid from the rat stomach. J Pharm Sci 56(7):843–847CrossRefPubMedGoogle Scholar
  44. 44.
    Nagashima R, Levy G (1969) Comparative pharmacokinetics of coumarin anticoagulants. V. Kinetics of warfarin elimination in the rat, dog, and rhesus monkey compared to man. J Pharm Sci 58(7):845–849CrossRefPubMedGoogle Scholar
  45. 45.
    Amsel LP, Levy G (1969) Drug biotransformation interactions in man. II. A pharmacokinetic study of the simultaneous conjugation of benzoic and salicylic acids with glycine. J Pharm Sci 58(3):321–326CrossRefPubMedGoogle Scholar
  46. 46.
    Jusko WJ, Levy G, Yaffe SJ (1970) Effect of age on intestinal absorption of riboflavin in humans. J Pharm Sci 59(4):487–490CrossRefPubMedGoogle Scholar
  47. 47.
    Tsuchiya T, Levy G (1972) Relationship between effect of activated charcoal on drug absorption in man and its drug adsorption characteristics in vitro. J Pharm Sci 61(4):586–589CrossRefPubMedGoogle Scholar
  48. 48.
    Hayton WL, Levy G (1972) Effect of complex formation on drug absorption. XII. Enhancement of intestinal absorption of prednisone and prednisolone by dialkylpropionamides in rats. J Pharm Sci 61(3):362–366CrossRefPubMedGoogle Scholar
  49. 49.
    Kamath BL, Levy G (1974) Letter: renal contribution to drug biotransformation. J Pharm Sci 63(8):1342–1343CrossRefPubMedGoogle Scholar
  50. 50.
    Oie S, Levy G (1977) Interindividual differences in the effect of drugs on bilirubin plasma binding in newborn infants and in adults. Clin Pharmacol Ther 21(5):627–632PubMedGoogle Scholar
  51. 51.
    Koysooko R, Ellis EF, Levy G (1975) Effect of ethanol on theophylline absorption in humans. J Pharm Sci 64(2):299–301CrossRefGoogle Scholar
  52. 52.
    Yacobi A, Levy G (1977) Comparative pharmacokinetics of coumarin anticoagulants XXIX: elimination kinetics and anticoagulant activity of (S)-(-)-warfarin in rats before and after chronic administration. J Pharm Sci 66(9):1275–1277CrossRefPubMedGoogle Scholar
  53. 53.
    Slattery JT, Levy G (1979) Acetaminophen kinetics in acutely poisoned patients. Clin Pharmacol Ther 25(2):184–195PubMedGoogle Scholar
  54. 54.
    Lai CM, Levy G (1978) Comparative pharmacokinetics of coumarin anticoagulants XXXVII: simultaneous in vivo displacement of dicumarol from serum protein and tissue binding sites by tolbutamide in rats. J Pharm Sci 67(10):1492–1493CrossRefPubMedGoogle Scholar
  55. 55.
    Giacomini KM, Nakeeb SM, Levy G (1980) Pharmacokinetic studies of propoxyphene I: effect of portacaval shunt on systemic availability in dogs. J Pharm Sci 69(7):786–789CrossRefPubMedGoogle Scholar
  56. 56.
    Whitfield LR, Levy G (1980) Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: magnitude and predictability of interindividual differences. Clin Pharmacol Ther 28(4):509–516CrossRefPubMedGoogle Scholar
  57. 57.
    Chou RC, Levy G (1981) Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. J Pharmacol Exp Ther 219(1):42–48PubMedGoogle Scholar
  58. 58.
    Cheung WK, Levy G (1989) Comparative pharmacokinetics of coumarin anticoagulants. XLIX: nonlinear tissue distribution of S-warfarin in rats. J Pharm Sci 78(7):541–546CrossRefPubMedGoogle Scholar
  59. 59.
    Morris ME, Levy G (1984) Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans. J Pharm Sci 73(8):1038–1041CrossRefPubMedGoogle Scholar
  60. 60.
    Wientjes MG, Levy G (1988) Nonlinear pharmacokinetics of aspirin in rats. J Pharmacol Exp Ther 245(3):809–815PubMedGoogle Scholar
  61. 61.
    Klockowski PM, Levy G (1988) Kinetics of drug action in disease states. XXV. Effect of experimental hypovolemia on the pharmacodynamics and pharmacokinetics of desmethyldiazepam. J Pharmacol Exp Ther 245(2):508–512PubMedGoogle Scholar
  62. 62.
    Nelson E, Hanano M, Levy G (1966) Comparative pharmacokinetics of salicylate elimination in man and rats. J Pharmacol Exp Ther 153(1):159–166PubMedGoogle Scholar
  63. 63.
    Levy G, Hollister LE (1964) Failure of U.S.P. disintegration test to assess physiologic availability of enteric coated tablets. N Y State J Med 64:3002–3005PubMedGoogle Scholar
  64. 64.
    Leonards JR, Levy G (1967) The role of dosage form in aspirin-induced gastrointestinal bleeding. Clin Pharmacol Ther 8(3):400–408PubMedGoogle Scholar
  65. 65.
    Levy G, Yaffe SJ (1968) The study of salicylate pharmacokinetics in intoxicated infants and children. Clin Toxicol 1:409–424CrossRefGoogle Scholar
  66. 66.
    O’Reilly RA, Levy G (1970) Kinetics of the anticoagulant effect of bishydroxycoumarin in man. Clin Pharmacol Ther 11(3):378–384PubMedGoogle Scholar
  67. 67.
    Ellis EF, Koysooko R, Levy G (1976) Pharmacokinetics of theophylline in children with asthma. Pediatrics 58(4):542–547PubMedGoogle Scholar
  68. 68.
    Levy G, Procknal J (1976) Letter: determination of salicylate and its metabolites in urine. Clin Chem 22(3):395PubMedGoogle Scholar
  69. 69.
    Soda DM, Levy G (1975) Inhibition of drug metabolism by hydroxylated metabolites: cross-inhibition and specificity. J Pharm Sci 64(12):1928–1931CrossRefPubMedGoogle Scholar
  70. 70.
    Wagner JG (1961) Biopharmaceutics: absorption aspects. J Pharm Sci 50:359–387CrossRefPubMedGoogle Scholar
  71. 71.
    Levy G, Jusko WJ (1965) Effect of viscosity on drug absorption. J Pharm Sci 54:219–224CrossRefPubMedGoogle Scholar
  72. 72.
    Levy G, Miller KE (1965) Drug absorption and exsorption kinetics in goldfish. J Pharm Sci 54(9):1319–1325CrossRefPubMedGoogle Scholar
  73. 73.
    Levy G, Schaeffer HJ (1962) Undergraduate research participation at the University of Buffalo School of Pharmacy. Am J Pharm Ed 26:200–204Google Scholar
  74. 74.
    Levy G (1974) An orientation to clinical pharmacokinetics. In: Levy G (ed) Clinical pharmacokinetics-A symposium. A.Ph.A. Academy of Pharmaceutical Sciences, Washington, pp 1–9Google Scholar
  75. 75.
    Gibaldi M, Levy G (1976) Pharmacokinetics in clinical practice. 1. Concepts. JAMA 235(17):1864–1867CrossRefPubMedGoogle Scholar
  76. 76.
    Gibaldi M, Levy G (1976) Pharmacokinetics in clinical practice. 2. Applications. JAMA 235(18):1987–1992CrossRefPubMedGoogle Scholar
  77. 77.
    Levy G (1978) A training program in clinical pharmacokinetics. Drug Intell Clin Pharm 12:204–209Google Scholar
  78. 78.
    Levy G (1977) How should clinical pharmaceutical scientists be trained? Am J Pharm Educ 41(4):394–396PubMedGoogle Scholar
  79. 79.
    DeVane CL (2015) Parents and mentors may be gone but they are never forgotten. Pharmacotherapy 35(1):1–3CrossRefPubMedGoogle Scholar
  80. 80.
    Levy G (1981) Pharmaceutical education in the future. Drug Intell Clin Pharm 15(7–8):590–593PubMedGoogle Scholar
  81. 81.
    Levy G (1981) Accreditation standards for doctor of pharmacy programs. Drug Intell Clin Pharmacol 15:470–472Google Scholar
  82. 82.
    Levy G (1983) Preparing for pharmacy’s future. Am J Pharmaceut Educ 47:332–334Google Scholar
  83. 83.
    Levy G (1984) Pharmaceutical education and the practice of pharmacy. Drug Intell Clin Pharm 18:829–832PubMedGoogle Scholar
  84. 84.
    Levy G (1991) The Pharm.D.: all or some? DICP 25(1):94–97PubMedGoogle Scholar
  85. 85.
    Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekke, New YorkGoogle Scholar
  86. 86.
    Levy G (1965) Aspirin, absorption rate and analgesic effect. Anesth Analg 44(6):837–841PubMedGoogle Scholar
  87. 87.
    Leonards JR, Levy G (1969) Biopharmaceutical aspects of aspirin-induced gastrointestinal blood loss in man. J Pharm Sci 58(10):1277–1279CrossRefPubMedGoogle Scholar
  88. 88.
    Levy G (1998) Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability. Clin Pharmacokinet 34(4):323–333CrossRefPubMedGoogle Scholar
  89. 89.
    Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20(2):173–201CrossRefPubMedGoogle Scholar
  90. 90.
    Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25(3):358–371PubMedGoogle Scholar
  91. 91.
    Teorell T (1937) Kinetics of distribution of substances administered to the body. I. The extravascular modes of administration. Arch Int Pharmacodyn Ther 57:205–225Google Scholar
  92. 92.
    Teorell T (1937) Kinetics of distribution of substances administered to the body. II. The intravascular modes of administration. Arch Int Pharmacodyn Ther 57:226–240Google Scholar
  93. 93.
    Paalzow L, Arbin A (1972) Serum and brain concentrations of pentazocine in relation to analgesic activity in mice. J Pharm Pharmacol 24(7):552–556CrossRefPubMedGoogle Scholar
  94. 94.
    Ramzan IM, Levy G (1985) Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J Pharmacol Exp Ther 234(3):624–628PubMedGoogle Scholar
  95. 95.
    Levy G, Regardh CG (1971) Drug biotransformation interactions in man. V. Acetaminophen and salicylic acid. J Pharm Sci 60(4):608–611CrossRefPubMedGoogle Scholar
  96. 96.
    Regardh CG (1975) Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol. Acta Pharmacol Toxicol (Copenh) 37(1):1–39Google Scholar
  97. 97.
    Reuning RH, Sams RA, Notari RE (1973) Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol New Drugs 13(4):127–141CrossRefPubMedGoogle Scholar
  98. 98.
    Kramer WG, Kolibash AJ, Lewis RP, Bathala MS, Visconti JA, Reuning RH (1979) Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man. J Pharmacokinet Biopharm 7(1):47–61CrossRefPubMedGoogle Scholar
  99. 99.
    Dost FH (1953) Der Blutspiegel. Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit, Thieme LeipzigGoogle Scholar
  100. 100.
    Gladwell M (2008) Outliers: the story of success, 1st edn. Little, Brown and Company, New YorkGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Pharmaceutical SciencesState University of New York at BuffaloBuffaloUSA

Personalised recommendations